Articles

Stephen Hayes

Biotechnology, rapid improvements were made as a department. In the current scenario, one investment priority areas, would keep most of the countries it to the list. Favorable to foreign investment in a thriving biotechnology industry as a potential area of ​​investment, while promoting a particular country, the country is often stressful. As part of the whole of Europe’s leading biotechnology so far, there were numerous reports that British 立 Tetakita hypothesis. Factors, the UK is to achieve in this position helped the strength of the industry. It has a huge chance when it comes to the UK biotech industry. It was also licensing its technology back 15 years

United Kingdom was relatively immature. At this moment in time perspective, the UK, it is good technology was, was that he was not successful in commercializing the technology. However, things have changed over the years. Many of the 450 biotechnology companies, the United Kingdom, to generate revenues and jobs to around £ 2.63 billion for 21 830 employees. These companies have the support from Japan Bioindustry Association, or BIA offered.

British

The market takes a leading position in European biotechnology. It is a mature market, has a strong product pipeline in the future to back the project. Pharmaceutical companies in the UK, for about 35% of products on the market. More like 41 percent of the new biologics are in the final phase of clinical studies and clinical trials have to.

Cambridge, Oxford and London, has been developed as a major center of biotechnology. These cities are also “golden triangle” was adopted. These cities will act as a hub for several major pharmaceutical companies. Certain other regions of the country, the biotech cluster known. They are scattered in the north-west and north-east of England.

The industry employs more people

40,000, can claim to most of them in the situation that are highly-qualified candidates have been absorbed. The industry has made rapid progress in the years since, has a great potential for the inclusion of a candidate in the coming years in the business of biotechnology. It has emerged as one of the industrial sector to count reliably.

is home to some of the largest investment funds in the biotech

. In Great Britain has a special expertise in certain areas of healthcare. These infections, monoclonal antibodies, tissue engineering, neurology and oncology and stem cell technology. Business Unit have a variety of multinational companies established their presence over the years from very small units.

biotechnology offshoot industries, the pharmaceutical industry. Pharmaceutical companies are produced in the manufacture of certain drugs, or a user selected number of drugs involved either. The production of these “over the counter” and prescription drugs are generics and branded medicines contain. Services of specialized companies, consulting and laboratory diagnostics and made available. Pharmaceutical carriers are mainly used in all these areas. The number of employment agencies, offering opportunities for adoption in this area.